Breast MRI for women with hereditary cancer risk

JAMA

Volumn 292, Issue 11, 2004, Pages 1368-1370

  Robson, Mark E ^a   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DIAGNOSTIC VALUE; EDITORIAL; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PRIORITY JOURNAL; ADULT; BREAST TUMOR; GENETICS; MUTATION; NOTE; RISK; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAGNETIC RESONANCE IMAGING; MUTATION; RISK;

EID: 4544261969     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.11.1368     Document Type: Editorial

References (28)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2 [published correction appears in Nature. 1996;379:749]. Nature. 1995;378:789-792.
3. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2 [published correction appears in Nature. 1996;379:749]. Nature. 1995;378:789-792,
4. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
5. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-1637.
6. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-164.
7. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055-1062.
8. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328-2335.
9. Narod SA, Brunet JS, Ghadirian P, et al, for Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
10. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-2256.
11. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
12. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Engl J Med. 2002;346:1616-1622.
13. Burke W, Daly M, Garber J, et al, for Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2. JAMA. 1997;277:997-1003.
14. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/genetics_screening.pdf. Accessibility verified August 12, 2004.
15. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924-930.
16. Scheuer L, Kauff ND, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
17. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer. 2002;102:91-95.
18. Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am. 2002;40:443-466.
19. Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of "high risk" women with proven or suspected familial (hereditary) breast cancer: first mid-term results of a multi-modality clinical screening trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:2.
20. Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res. 2002;21:115-124.
21. Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001;93:1095-1102.
22. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000;63:53-60.
23. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001;19:3524-3531.
24. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol. 2003;181:619-626.
25. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317-1325.
26. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437.
27. Liberman L. Breast cancer screening with MRI: what are the data for patients at high risk? N Engl J Med. 2004;351:497-500.
28. BiueCross BlueShield Association. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Available at: http://www.bluecares.com/tec/vol18/18_15.html. Accessed August 5, 2004.